5PSQ-064 Use of sorafenib in cellular hepatocarcinoma in routine clinical practice

BACKGROUND: Sorafenib is a multikinase inhibitor approved for the treatment of hepatocellular carcinoma (HCC). In clinical trials sorafenib treatment resulted in a median overall survival of 9.2 months and a median time to progression of 5.5 months (SHARP study). PURPOSE: To describe the results of...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Hosp Pharm
Autors principals: Saavedra, FJ Parada, Agustí, R Candeas, Calafat, JM Miñana, Blanch, CL Aracil, Sotoca, M Gilabert, Arnaiz, JA Schoenenberger
Format: Artigo
Idioma:Inglês
Publicat: BMJ Group 2018
Matèries:
Section 5: Patient safety and quality assurance
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535212/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.418
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars